PTC Therapeutics insider plans sale of 5,149 shares

PTC Therapeutics insider Matthew Klein has filed a Rule 144 notice to sell 5,149 shares of common stock.

Rhea-AI Filing Summary

PTC Therapeutics insider Matthew Klein has filed a Rule 144 notice to sell 5,149 shares of common stock. The planned sale is to be executed through Fidelity Brokerage Services, with an aggregate market value of $396,203.19, and an approximate sale date of January 6, 2026 on NASDAQ. The shares to be sold were acquired on January 5, 2026 through restricted stock vesting as compensation from the issuer.

PTC Therapeutics had 80,288,305 shares of common stock outstanding. Over the prior three months, Matthew Klein sold 3,428 shares for gross proceeds of $271,062.93 on December 2, 2025, and 8,089 shares for $619,921.55 on December 30, 2025. By signing, the seller represents they are not aware of undisclosed material adverse information about the company’s operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for PTC Therapeutics (PTCT) disclose?

It discloses that Matthew Klein plans to sell 5,149 shares of PTC Therapeutics common stock under Rule 144, through Fidelity Brokerage Services on or around January 6, 2026.

How many PTC Therapeutics shares is the insider planning to sell?

The filing states an intended sale of 5,149 shares of common stock, with an aggregate market value of $396,203.19.

How were the PTC Therapeutics shares being sold acquired?

The 5,149 shares of common stock were acquired on January 5, 2026 via restricted stock vesting from the issuer, described as compensation.

What prior stock sales by Matthew Klein in PTCT are disclosed?

In the past three months, Matthew Klein sold 3,428 shares for $271,062.93 on December 2, 2025, and 8,089 shares for $619,921.55 on December 30, 2025.

How many PTC Therapeutics shares were outstanding according to the filing?

The notice reports that 80,288,305 shares of common stock were outstanding for PTC Therapeutics.

What representation does the selling insider make in the Form 144 for PTCT?

By signing, the seller represents that they do not know any material adverse information about PTC Therapeutics’ current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/06/2026 - 04:46 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001808968
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PTC THERAPEUTICS, INC.
SEC File Number	001-35969
Address of Issuer	500 WARREN CORPORATE CENTER DRIVE WARREN NEW JERSEY 07059
Phone	9082227000
Name of Person for Whose Account the Securities are To Be Sold	Klein Matthew B.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	5149	396203.19	80288305	01/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/05/2026	Restricted Stock Vesting	Issuer			5149	01/05/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Matthew Klein 500 Warren Corporate Center Drive Warren NJ 07059	Common	12/02/2025	3428	271062.93
Matthew Klein 500 Warren Corporate Center Drive Warren NJ 07059	Common	12/30/2025	8089	619921.55

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	01/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Gary Redman, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Matthew Klein
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)